kidney disease

(Credit: Peakstock on Shutterstock)

In A Nutshell

  • A Large Awareness Gap: The CDC estimates about 37 million U.S. adults have chronic kidney disease and about 87% of those 20 and older with it don’t know it, though its single-test survey method may overstate the total.
  • Two Tests, Two Jobs: A blood test (eGFR) estimates how well the kidneys filter while a urine test (UACR) detects leaking albumin, and research shows either one alone can miss a problem.
  • Test, Then Confirm: Guidelines back regular testing for people with risk factors such as diabetes and require abnormal results to last at least 3 months before diagnosis, while routine screening of all healthy adults remains unsettled.

Your checkup blood work comes back normal, creatinine included, and you leave assuming your kidneys are fine. They may be. But that blood test answers only one question about your kidneys, and the second question needs a urine sample that many at-risk patients never give.

Chronic kidney disease rarely announces itself. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) says early kidney disease usually causes no symptoms and that “testing is the only way to know how well your kidneys are working.” Getting the full picture takes two tests, one of blood and one of urine, and each can catch what the other misses. Without both, the disease can go unnoticed, and nationally, it usually does.

Why Does Kidney Disease So Often Go Unnoticed?

Because early disease is usually silent.

The Centers for Disease Control and Prevention estimates that about 14% of U.S. adults, roughly 37 million people, have chronic kidney disease (CKD). It also estimates that about 87% of adults 20 and older with CKD don’t know they have it. The figures were updated in March 2026. They come from blood and urine tests given in the August 2021 to August 2023 National Health and Nutrition Examination Survey, and they cover CKD stages 1 through 4. An earlier snapshot points the same way: Healthy People 2030, using 2017-2020 survey data, put awareness among adults with CKD at 10.5%.

Without symptoms, there may be nothing to send a person to the doctor. Filtering ability can fall, or protein can leak into the urine, while the person feels fine.

These numbers describe the country as a whole, not individual diagnoses. The CDC notes that its estimate relies on one blood and urine measurement per person and doesn’t check whether abnormal results lasted, as kidney guidelines require. As a result, the agency says, CKD in its report “might be overestimated.”

Chronic kidney disease model being held by doctor.
Chronic kidney disease model. (© manassanant – stock.adobe.com)

Why Isn’t A Routine Blood Test Enough?

Because the two tests measure different problems.

A standard blood test measures creatinine, a waste product, which is used to calculate the estimated glomerular filtration rate, or eGFR. That number shows how well the kidneys filter blood. A spot urine albumin-to-creatinine ratio, or UACR, looks for albumin. Healthy kidneys hold on to this protein, while damaged kidney filters let some of it escape into the urine. The NIDDK says a GFR of 60 or higher is in the normal range, while a result below 60 may mean kidney disease. Under the KDIGO 2024 guideline, a UACR of 30 milligrams per gram or higher counts as abnormal.

Each test can catch what the other misses. The National Kidney Foundation notes that urine albumin can flag kidney disease in people whose eGFR still looks normal. In the other direction, the American Diabetes Association’s Standards of Care note that many people with diabetes show lowered eGFR with no albuminuria at all.

The observational Joslin Kidney Study, published in Diabetes Care, followed 534 adults with type 1 diabetes for 4 to 10 years, with a median of 8 years. At the start, each had either normal urine albumin or moderately raised albumin. Steady loss of filtering ability, at least 3.3% a year, showed up in 10% of those with normal albumin and 35% of those with moderately raised albumin. The researchers concluded that kidney function decline in type 1 diabetes begins while albumin levels are still normal, so a urine test alone could have missed some people whose kidneys were already declining. The study was limited to type 1 diabetes and was not randomized, so it can’t show that the same pattern holds for other groups.

Even so, the urine test often gets skipped. A 2023 study in JAMA Network Open reviewed health records for 192,108 U.S. adults with hypertension or diabetes who had at least two outpatient visits in 2017 and 2018. Only 17.5% had their urine albumin tested. The researchers built a model from national survey data to estimate albuminuria among patients who were never tested, and concluded that about two-thirds of patients with albuminuria had not been identified. Patients who were tested had higher odds of receiving kidney-protective medicines.

The study was observational, though, and records could miss care received elsewhere, so it can’t show that testing itself led to better treatment. It was supported through a collaborative agreement with Bayer.

What Happens After One Abnormal Result?

It needs confirmation.

The KDIGO 2024 guideline advises repeating tests after an abnormal eGFR or UACR result turns up. It also requires kidney abnormalities to last at least 3 months before chronic disease is diagnosed. The guideline warns that a single abnormal reading could reflect a recent acute kidney injury, which is a sudden drop in kidney function, rather than lasting disease.

Urine albumin also varies from day to day. The ADA lists exercise in the previous 24 hours, infection, fever, heart failure, very high blood sugar, menstruation and very high blood pressure as things that can raise UACR without any kidney damage. Because measurements can differ by more than 20%, the ADA advises that 2 of 3 urine samples collected over 3 to 6 months be abnormal before a person with diabetes is considered to have raised albuminuria.

What Does The Evidence Support For Screening?

Targeted testing, most clearly.

The NIDDK names diabetes, high blood pressure, heart disease and a family history of kidney failure as reasons to get checked. The ADA recommends eGFR and UACR testing for everyone with type 2 diabetes and for people who have had type 1 diabetes for at least 5 years, and a Cleveland Clinic summary of the 2026 standards notes that yearly testing remains the baseline.

Testing everyone else is less settled. In its 2012 statement, the U.S. Preventive Services Task Force concluded there wasn’t enough evidence to judge whether routine screening of adults without symptoms or a CKD diagnosis does more good than harm. That statement did not cover testing done to manage conditions such as diabetes or hypertension. The task force is now updating its recommendation. It finalized a research plan in July 2023 but, as of September 2026, had not released a draft.

For someone with risk factors, a creatinine result alone is only half the picture. Checking eGFR alongside UACR, and then confirming any abnormal result over time, can reveal kidney changes that symptoms won’t, without treating one result as a diagnosis.

Disclaimer: This article combines national surveillance estimates (CDC, Healthy People 2030), clinical practice guidelines (KDIGO, the American Diabetes Association, the U.S. Preventive Services Task Force) and two observational studies. It is for general information and is not medical advice. The national prevalence and awareness figures come from survey participants tested once, so they may overstate how many people have lasting kidney disease. Neither study tested whether screening people without symptoms improves their health, and that question is still under review by the U.S. Preventive Services Task Force. Anyone with questions about their kidney health or test results should talk with a health care provider.


Research Notes

Limitations

CDC national estimate (2026 update). The CDC estimate is based on a single urine albumin-to-creatinine ratio and serum creatinine measurement per survey participant and does not account for whether abnormal results persisted, as KDIGO criteria require; the agency states that CKD in its report might be overestimated. It covers stages 1 through 4 only, because stage 5 had too few participants. The awareness figure applies to adults aged 20 and older.

Healthy People 2030 (CKD-02). The 10.5% awareness value reflects 2017-2020 survey data, age-adjusted to the 2000 standard population. The objective page itself does not state the CKD definition or the survey question used to measure awareness; those details sit in the program’s methodology section, which was not reviewed.

Joslin Kidney Study (Krolewski et al., 2014). The study was descriptive and observational, drawn from a single specialty clinic in New England, and limited to adults with type 1 diabetes, so applicability to type 2 diabetes or the general population is uncertain. Kidney function was estimated, not directly measured, using a combined creatinine-cystatin C equation that the authors note has not been validated in type 1 diabetes and may undercount early decline. People with heavy albumin loss (macroalbuminuria) were excluded at entry.

JAMA Network Open albuminuria study (Chu et al., 2023). Prevalence among the 82.5% of patients who were never tested was estimated with a model built from 2007-2018 national survey (NHANES) data, not measured; the authors note the model tended to underestimate albuminuria, so true prevalence is likely higher. Electronic health records can miss care received in other health systems. The design was observational, so the link between testing and treatment may reflect other factors. Patients without an eGFR value were excluded.

Guidelines (KDIGO 2024, ADA 2026, USPSTF 2012). Many KDIGO statements cited here are “practice points” rather than graded recommendations. The ADA guidance applies specifically to people with diabetes; its 2025 and 2026 screening recommendation (11.1a) names who should be tested but does not itself state a frequency, and the 2026 section page could not be opened directly for this package. The USPSTF statement dates to 2012 and is listed by the task force as out of date while an update is in progress.

Funding and Disclosures

Chu et al. (JAMA Network Open, 2023): Supported through a collaborative agreement with Bayer; Bayer-employed coauthors participated in study design, analysis and manuscript preparation. One coauthor is employed by Gilead Sciences. Several academic authors reported consulting fees or grants from pharmaceutical companies (including AstraZeneca and Boehringer Ingelheim) and NIH grants outside this work, per the article’s disclosures on PubMed Central.

Krolewski et al. (Diabetes Care, 2014): Funded by National Institutes of Health grant DK-41526. Two authors (Krolewski and Niewczas) disclosed being co-inventors on a patent application for kidney disease diagnostic methods, assigned to Joslin and later transferred to EKF Diagnostics; no other relevant conflicts reported.

KDIGO 2024 and ADA Standards of Care 2026: Funding and conflict-of-interest disclosures for these guideline panels were not reviewed for this package; they are published in the guideline documents themselves.

Publication Details

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH. “Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria.” Diabetes Care, Volume 37, Issue 1, pages 226–234 (published online December 2013; January 2014 issue). DOI: 10.2337/dc13-0985. Affiliations: Joslin Diabetes Center and Harvard Medical School, Boston; Jagiellonian University Medical College, Krakow, Poland; Juntendo University School of Medicine, Tokyo, Japan; University of Minnesota.

Chu CD, et al. (coauthors include Julio A. Lamprea-Montealegre, Delphine S. Tuot, Michael G. Shlipak and Michelle M. Estrella of UCSF; Fang Xia of Gilead Sciences; and Yuxian Du, Rakesh Singh, Ralph Gualtieri, Nick Liao, Sheldon X. Kong and Todd Williamson of Bayer US LLC) “Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease.” JAMA Network Open, Volume 6, Issue 7, article e2326230 (published July 27, 2023). DOI: 10.1001/jamanetworkopen.2023.26230. Affiliations: University of California, San Francisco, and its Kidney Health Research Collaborative; San Francisco VA Health Care System; Gilead Sciences; Bayer US LLC. (Full author order not confirmed; check the article page before print.)

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.” Kidney International, Volume 105, Issue 4S, pages S117–S314 (April 2024). DOI: 10.1016/j.kint.2023.10.018.

American Diabetes Association Professional Practice Committee. “11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026.” Diabetes Care, Volume 49, Supplement 1, beginning page S246 (January 2026 supplement; released online December 2025). Article page.

U.S. Preventive Services Task Force (Moyer VA). “Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement.” Annals of Internal Medicine, Volume 157, Issue 8, pages 567–570 (October 16, 2012; online August 28, 2012). DOI: 10.7326/0003-4819-157-8-201210160-00533. USPSTF topic page (update in progress; final research plan published July 2023).

Non-academic sources

  • Centers for Disease Control and Prevention. “Chronic Kidney Disease in the United States.” Updated March 31, 2026. cdc.gov
  • Office of Disease Prevention and Health Promotion. Healthy People 2030 objective CKD-02, “Increase the proportion of adults with chronic kidney disease who know they have it.” odphp.health.gov
  • National Institute of Diabetes and Digestive and Kidney Diseases. “Chronic Kidney Disease Tests & Diagnosis.” niddk.nih.gov
  • National Kidney Foundation. “Albuminuria (proteinuria).” kidney.org
  • HCPLive. “Nearly 9 in 10 US Adults With CKD Don’t Know They Have It,” September 24, 2026. hcplive.com

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor